Peptides Unpacked Ep 02: A Real Conversation on GLP-1s

GLP-1 medications are everywhere, and for people who have fought their weight for decades, the results can feel like someone finally turned down the volume on cravings and “food noise.” I’m Krista Guidenti, and I’m equal parts fascinated and cautious. That mix matters, because therapies that change biology this fast rarely come without trade-offs, and I want us to be able to hold hope and scrutiny at the same time.We start with the basics of GLP-1 (glucagon-like peptide-1) and why drugs like Ozempic, Wegovy, and Mounjaro can change appetite, satiety, and blood sugar control in a way that goes beyond willpower. Then we get honest about what people are reporting and what clinicians are watching: nausea, constipation, reflux, fatigue, and the more serious concerns that keep coming up in the conversation, including pancreatitis and gallbladder issues. We also dig into one of my biggest worries, muscle loss, and why preserving lean mass is non-negotiable for metabolism, strength, bone health, and healthy aging, especially for women in perimenopause and menopause.Cancer questions come up a lot, so I walk through where those fears originated (early high-dose rodent studies and thyroid warnings), what human data generally suggests so far, and why “no clear signal” is not the same as decades of certainty. From there, we explore what happens when you stop GLP-1s, why weight regain may point to obesity as a chronic disease, and why people are experimenting with microdosing and intermittent dosing in search of a minimum effective dose. Finally, we look at what’s next, including retatrutide and the rise of even more powerful multi-pathway obesity drugs.If you’re navigating GLP-1 weight loss, obesity medicine, and long-term metabolic health, listen, share this with a friend who’s curious, and leave a review so more people can find the show.